PrEP has been used in NSW by high risk individuals since 2011, with a significant increase in 2016.
It has been limited by cost and availability.
Who should have access to PrEP, given limited resources? - The high risk patient approach.
Demonstration study - PRELUDE 2014-2016 government purchased generics
Estimated 4% (12 of 300) of PRELUDE study patients would have seroconverted, but none did.
Individuals are usually highly motivated.
Blood tests in these studies suggest very high levels of adherence.
The implementation trial EPIC-NSW.
Estimated that there must be 3700 high-risk individuals in NSW
It was estimated that the highest risk 11% of the gay community would comprise 3700 people, but so far we have recruited 4000.
EPIC aimed to target this group and enroll them on a PrEP study.
EPIC-NSW estimates 150 participants should have seroconverted by the end of the study, it is early yet, but so far none have.